Do RAMPs affect other receptors too?

Yes. They were first described in the context of the calcitonin receptor-like receptor, where they generate CGRP and adrenomedullin receptor phenotypes, and RAMP interactions have since been reported for a range of other receptors. The amylin case is the one that matters most for metabolic pharmacology.

Is the amylin receptor a real receptor then?

It is a real functional entity with defined ligand preferences - it just is not a single gene product. Referring to it as a receptor is correct; assuming that implies a dedicated gene is not.

Does this explain the nausea seen with amylin agonists?

Not directly. Overlapping activity across an assembled receptor family is a reason to expect effects beyond the intended one, but attributing a specific adverse effect to a specific complex requires evidence this line of reasoning does not supply.

Why does pramlintide exist if amylin aggregates?

Because substituting the residues that drive aggregation produces a molecule that retains useful receptor activity without forming fibrils. It is the same engineering logic that underlies every later amylin analogue, applied first.

GLP-1 & Incretin Science

There Is No Amylin Receptor Gene

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Amylin receptors are generated from the calcitonin receptor gene product when it associates with one of three receptor activity-modifying proteins. There is no separate amylin receptor gene at all, which is the reason amylin, calcitonin and CGRP pharmacology cannot be separated cleanly.

Key facts

Core receptor: Calcitonin receptor, CTR
Accessory proteins: RAMP1, RAMP2, RAMP3
Resulting phenotypes: AMY1, AMY2, AMY3
Related receptor: Calcitonin receptor-like receptor, giving CGRP and adrenomedullin receptors
Determines ligand phenotype: The RAMP amino-terminal domain
Determines expression level: The RAMP transmembrane domain and C-terminus
Consequence: Amylin, calcitonin and CGRP pharmacology overlap by construction
Key paper: Zumpe ET et al., Biochem Biophys Res Commun 2000 (PMID 10623626)

A receptor assembled rather than encoded

Most drug targets correspond to a gene. Look up the GLP-1 receptor and you find GLP1R. Look up the amylin receptor and you find nothing, because there is no such gene. Amylin receptors are made when the protein encoded by the calcitonin receptor gene associates with one of three receptor activity-modifying proteins, and the resulting complex has ligand preferences that neither component has alone. The same RAMPs acting on a related protein, the calcitonin receptor-like receptor, generate the receptors for CGRP and adrenomedullin instead. One family of accessory proteins reconfigures two core receptors into at least six pharmacological identities.

What the chimera experiments showed

Zumpe and colleagues asked which part of a RAMP does the work by building chimeras: the amino-terminal domain of RAMP1 attached to the transmembrane domain and carboxy terminus of RAMP2, and the reverse. Co-transfecting these with a human calcitonin receptor isoform into COS-7 cells produced amylin binding sites, and the two halves of the RAMP turned out to control different things. Highest specific binding occurred with RAMP1 or with the chimera carrying RAMP1's transmembrane and C-terminal regions, indicating those regions govern how much receptor is expressed. The phenotype - what the receptor prefers to bind - was determined primarily by the amino terminus, with RAMP1 and RAMP1/2 producing receptors of higher affinity for human CGRP-alpha and lower affinity for human calcitonin than the RAMP2-derived ones.

Why this is the missing piece under amylin drug development

Cagrilintide, petrelintide and the other engineered amylin analogues are usually described in terms of their stability and their duration. What is rarely said is that the receptor they engage is a composite whose identity depends on which accessory protein a given cell happens to express, and that expression varies between tissues. Selectivity for an amylin analogue therefore does not mean selectivity for one protein - it means a preference across a family of assembled complexes that also read calcitonin and CGRP. That is a harder engineering problem than selecting between two distinct receptors, and it is a structural reason why amylin agonists have overlapping activities that are difficult to design out.

Why native amylin is a hard starting point

Human amylin aggregates into amyloid fibrils, which is both a formulation obstacle and a biological one, and every clinical amylin agonist is an engineered analogue built to avoid it. Pramlintide, the licensed precedent, substitutes proline residues at positions that promote aggregation - proline disrupts the beta-sheet structure fibrils require. The consequence is that no clinical amylin agent is amylin. Each is a different molecule with its own profile across an assembled receptor family, which is one more reason results do not transfer between them.

What it means for reading a comparison

When one amylin analogue's data is used to argue for another, two assumptions are being made silently: that the two molecules engage the assembled receptors similarly, and that the tissues that matter express the same RAMP complement. Neither follows from both compounds being called amylin agonists. This is a sharper version of a general rule in this library - that class labels describe intent rather than pharmacology - and the amylin field is where it bites hardest, because the receptor itself is not a fixed object.

Where this sits relative to the incretins

The GLP-1 receptor is a single gene product and its agonists compete for one defined target, which is part of why cross-compound comparison in that class is comparatively tractable. Amylin is not like that. Combination products pairing an amylin analogue with a GLP-1 agonist are therefore pairing a well-defined receptor interaction with a less well-defined one, and the uncertainty in the second component does not disappear because the first is understood. None of these compounds is supplied on this site.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Do RAMPs affect other receptors too?: Yes. They were first described in the context of the calcitonin receptor-like receptor, where they generate CGRP and adrenomedullin receptor phenotypes, and RAMP interactions have since been reported for a range of other receptors. The amylin case is the one that matters most for metabolic pharmacology.
Is the amylin receptor a real receptor then?: It is a real functional entity with defined ligand preferences - it just is not a single gene product. Referring to it as a receptor is correct; assuming that implies a dedicated gene is not.
Does this explain the nausea seen with amylin agonists?: Not directly. Overlapping activity across an assembled receptor family is a reason to expect effects beyond the intended one, but attributing a specific adverse effect to a specific complex requires evidence this line of reasoning does not supply.
Why does pramlintide exist if amylin aggregates?: Because substituting the residues that drive aggregation produces a molecule that retains useful receptor activity without forming fibrils. It is the same engineering logic that underlies every later amylin analogue, applied first.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum